Foreign Collaboration Proposals in Drug Sector

1879. SHRI ANANT RAM JAISWAL :

SHRIMATI SATYA BAHIN :

Will the PRIME MINISTER be pleased to state :

(a) what are the details of foreign collaboration proposals cleared in the drug sector during the yast three years yearwise ;

(b) what were the names of the Indian companies/foreign companies/products involved, terms and period of payment and whether the projects, have been implemented so far ; and

(c) what are the details of the proposals for sharing of penicillin know-how received by HAL and how much payment is involved in each case ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS WITH ADDITIONAL CHARGE OF THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF ELECTRONICS AND DEPARTMENT OF OCEAN DEVELOPMENT (SHRI EDUARDO FALEIRO) : (a) to (c) Information will be collected and laid on the Table of the House.

Utilisation of amounts recovered from drug companies under DPEA

1880. SHRI RAJNI RANJAN SAHU :

SHRIMATI SATYA BAHIN :

Will the PRIME MINISTER be pleased to refer to the answer to Starred Question 80 given in the Rajya Sabha on 29th April, 1993 and state :

(a) what are the purposes for which amount recovered or recoverable to DPEA can be utilised ;

(b) whether it is a fact that there is no provision under DPCO, 1987 to give effect to those purposes and what has been the opinion of the Legal Department on this issue ;

(c) whether it is a fact that his Ministry has not paid any heed to the advice obtained from the Legal Department on this issue ; and

(d) whether it is also a fact that during the last three years recoveries in respect of almost about 100 cases is lying pending assessment ; and

(e) what steps have been taken to expedite the same ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS WITH ADDITIONAL CHARGE OF THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF ELECTRONICS AND DEPARTMENT OF OCEAN DEVELOPMENT (SHRI EDUARDO FALEIRO) : (a) to (c) The purposes for which amount recovered/recoverable into the DPEA can be utilised, are indicated in Para 17 (2) (a) & (b) of the DPCO, 1979 and Para 14(2) of the DPCO, 1987.

(d) and (e) All efforts have been made to obtain the requisite data from the companies and to compute their liabilities. The companies have also been cautioned that in case they do not furnish the required data/information, their liabilities would be assessed on the basis of whatever data become available.

Production of Betamethasone by M/s. Glaxo

1881. SHRI H. HANUMANTHAPPA : Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 3105 given in the Rajya Sabha on 19th August, 1993 and state :

(a) whether the Ministry of Chemical and Fertilizers has verified that M/s. Glaxo is the exclusive producer of Betamethasone formulations and there is no follower ;

(b) the reasons for which the 8 per cent incidentals were given to this company and whether it has led to unintended benefit of Rs. 16 crores per annum ;

(c) whether it is a fact that similar unintended benefit on Ranitidine, Cephalexin and several other formulations are being enjoyed by this company; and

(d) what steps have been taken to investigate the whole matter ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS WITH ADDITIONAL CHARGE OF THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF ELECTRONICS AND DEPARTMENT OF OCEAN DEVELOPMENT (SHRI EDUARDO FALEIRO): (a) There are companies other than M/s. Glaxo producing Betamethasone formulations.

(b) and (c) Incidentals are allowed in cases of ceiling packs as per established procedure of price-fixation.

(d) Does not arise.

Determination of liability for a company

1882. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 3111 given in Rajya Sabha on 19th August, 1993 and state:

(a) whether there is any stay on determination of liability arising out of overcharging of prices in post-DPCO, 1979 period;

(b) whether it is a fact that liability has not been deliberately worked out for the last three years to doll out this company;

(c) what are the reasons for not determining the liability and whether it is a fact that the company has given agency and distributorship to the kin of bureaucrates to stall the determination of liability for the post DPCO 1979 period; and

(d) what is the name of the salt of Betamethasone that has been price decontrolled for the company and what were the specific basis for decontrolling its price ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS WITH ADDITIONAL CHARGE OF THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF ELECTRONICS AND DEPARTMENT OF OCEAN DEVELOPMENT (SHRI EDUARDO FALEIRO): (a) and (b) No, Sir.

(c) The company has been asked to furnish the details/data to the Government for working out the liability for the relevant period. No specific instance of giving of any agency and distributorship to the kin of any official of this Department has come to the notice of the Government.

(d) The name of the salt of bulk drug Betamethasone is Betamethasone Di-Sodium Phospate and the same has been exempted on the basis of R & D efforts undertaken by the company viz (i) improvement in the production efficiency (ii) reduction in the cost of production (iii) saving in Foreign Exchange, (iv) Production from basic stage.

Bulk drugs wrongly included under price control

1883. PROF. I. G. SANADI: Will the PRIME MINISTER be pleased to refer to the answer to Starred Question 329 given in Rajya Sabha dated on the 19th August, 1993 and state:

(a) the names of the bulk drugs which were wrongly included under price control as per the representations received by Government in the matter;

(b) the names of the drugs which were excluded from price control against the criteria of Kelkar Committee;

(c) the reasons for which these anomalies were not removed during the last three years and benefits were given to producers;

(d) whether it is a fact that even prices of price controlled drugs have not been complied with by the producers, if so, what are the details in this regard; and

(e) whether any responsibility has been fixed for maintaining the status quo ?